Zogenix (ZGNX) Misses Q4 EPS by 20c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
Go back to Zogenix (ZGNX) Misses Q4 EPS by 20c, Revenues Beat
March 4, 2020 5:56 AM EST
Zogenix, Inc. (NASDAQ: ZGNX) announced today that it has priced an underwritten public offering of 8,520,000 shares of its common stock at a price to the public of $23.50 per share. The gross proceeds to Zogenix from the offering, before underwriting discounts and commissions and offering... More
February 28, 2020 7:08 AM EST
Ladenburg Thalmann analyst Michael Higgins lowered the price target on Zogenix, Inc. (NASDAQ: ZGNX) to $25.00 (from $35.00) while maintaining a Neutral rating.... More
February 27, 2020 8:06 AM EST
Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that the U.S. Food and Drug Administration (FDA) has extended the review period for the New Drug Application (NDA) for FINTEPLA® for the treatment of seizures associated with Dravet syndrome. The new Prescription Drug User Fee Act (PDUFA) target... More
